- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03417999
Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease
September 19, 2023 updated by: Kelly Grogan, Children's Hospital of Philadelphia
Dose Escalation Pharmacokinetic Study of Intranasal Atomized Dexmedetomidine in Pediatric Patients With Congenital Heart Disease
The main objectives of the study are to determine peak plasma drug concentration levels and corresponding time of dexmedetomidine following intranasal administration in children age ≥1 mo to ≤ 6 yr with congenital heart disease undergoing an elective diagnostic or interventional cardiac catheterization procedure.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The high anxiety levels that children may experience during the preoperative period may be associated with negative medical, psychological, and social consequences.
To reduce this stress, and to facilitate separation from parents and the induction of anesthesia, children are often given a sedative prior to undergoing a procedure.
Dexmedetomidine is a highly selective a2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties.
While off-label in its use, the administration of dexmedetomidine by the intranasal route has become a popular and effective technique for sedation in children because it is non-invasive, easy to administer, well tolerated, and relatively fast in onset.
Despite this, little consistent data have been published on its onset time, duration of action, or optimal dose.
The only available pharmacokinetic (PK) data on dexmedetomidine in pediatric patients is in children who were administered IV dexmedetomidine.
We are proposing a prospective open-label inter-subject cohort dose-escalation pharmacokinetic study to obtain peak dexmedetomidine drug concentration level in plasma and the corresponding time point following intranasal administration in the pediatric patient with cardiac disease.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19106
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 6 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female subjects age ≥1 mo to ≤6 yo.
- Subjects must have congenital heart disease.
- American Society of Anesthesiology (ASA) Physical Status 1-3.
- Subjects scheduled for elective cardiac interventional or diagnostic catheterization anticipated to last ≥ 3hours.
- Subjects spontaneously ventilating with a natural airway scheduled for elective cardiac interventional or diagnostic catheterization anticipated to last ≥ 2 hours.
- Subjects must have reliable intravascular access from which to draw blood samples.
Exclusion Criteria:
- History of allergic reaction or sensitivity to dexmedetomidine.
- Nasal pathology preventing the administration of drug.
- Patients that are on maintenance medications that could inhibit or induce the CYP2A6 enzyme.
- Cardiac conduction abnormalities defined as second or third degree heart block or pacemaker dependence.
- Bradycardia, defined by age, upon arrival in the preoperative care area.
- Hepatic dysfunction defined as a history of hepatic dysfunction AND an Alanine Aminotransferase (ALT) value greater than 2 times normal in the 6 months prior to study drug administration.
- The subject has received dexmedetomidine or clonidine within 1 week of the study date.
- BMI >30.
- Patients previously enrolled in this study.
- Any investigational drug use within 30 days prior to enrollment.
- Wards will not be eligible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Cohort 1A:
Cohort 1B:
|
Dose-escalation of atomized intranasal dexmedetomidine
Other Names:
|
Experimental: Cohort 2
|
Dose-escalation of atomized intranasal dexmedetomidine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Samples Obtained Per Subject
Time Frame: Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Following the administration of atomized intranasal dexmedetomidine, serum samples will be drawn at 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 and 300 minutes post drug administration.
This is the number of samples obtained per subject.
|
Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Time of Peak Drug Concentration Level of Dexmedetomidine
Time Frame: Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Following the administration of atomized intranasal dexmedetomidine, serum samples will be drawn at 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 and 300 minutes post drug administration.
The time of peak drug concentration will be determined based on this data.
|
Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Serum Drug Concentration Levels of Dexmedetomidine
Time Frame: Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Following administration of atomized intranasal dexmedetomidine, serum samples will be obtained at the following times post administrations: 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes.
Peak concentration will be determined based on this data.
|
Up to 5 hours - 0, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post drug administration
|
Dose-limiting Toxicities (DLT) and/or Maximum Plasma Level > 1000 pg/mL
Time Frame: Subjects were monitored for 6 hours after the administration of study drug.
|
Dose-limiting toxicities (DLT) include bradycardia, hypotension, new intraventricular conduction abnormality or any serious adverse event possibly, probably, or definitely related to intranasal dexmedetomidine administration that occured after the administration of the intranasal dexmedetomidine and through the completion of PK sampling.
Bradycardia, hypotension, or new intraventricular conduction abnormalities that occured after the administration of intravenous dexmedetomidine given by the primary anesthesia team as part of usual clinical care were not considered DLTs but were considered an adverse event.
Any events that could not be explained by the intervention that the patient was undergoing were assumed to be related to the study drug.
|
Subjects were monitored for 6 hours after the administration of study drug.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kelly L Grogan, MD, Children's Hospital of Philadelphia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2018
Primary Completion (Actual)
October 12, 2021
Study Completion (Actual)
October 12, 2021
Study Registration Dates
First Submitted
January 8, 2018
First Submitted That Met QC Criteria
January 30, 2018
First Posted (Actual)
January 31, 2018
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
September 19, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Diseases
- Heart Defects, Congenital
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 17-014084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
Vanderbilt University Medical CenterEnrolling by invitationCongenital Heart Disease | Congenital Heart Defect | Congenital Heart MalformationsUnited States
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
Assistance Publique Hopitaux De MarseilleRecruitingComplex Congenital Heart DiseaseFrance
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's HospitalEnrolling by invitation
-
Universitas Sumatera UtaraIndonesia UniversityCompletedCyanotic Congenital Heart DiseaseIndonesia
-
Paul FinnCompletedPediatric Congenital Heart DiseaseUnited States
-
The Hospital for Sick ChildrenTerminatedCongenital Heart Disease (CHD)
-
The Hospital for Sick ChildrenCompletedCongenital Heart Disease (CHD)Canada
-
Carl Backes, MDChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsRecruitingCongenital Heart Disease (CHD)United States, Canada
Clinical Trials on Dexmedetomidine
-
Cairo UniversityUnknownSpinal Anesthesia DurationEgypt
-
Guangzhou Women and Children's Medical CenterCompletedAmbulatory Surgical ProceduresChina
-
Seoul National University Bundang HospitalCompleted
-
The First Affiliated Hospital with Nanjing Medical...CompletedPostoperative Pain | Breast Feeding | Analgesia ObstetricalChina
-
Guangzhou General Hospital of Guangzhou Military...CompletedPharmacodynamic InteractionChina
-
National Cancer Institute, EgyptCompleted
-
University Hospital DubravaRecruitingAortic Valve Stenosis | Systemic Inflammatory ResponseCroatia
-
Guangzhou General Hospital of Guangzhou Military...Completed
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownArteriovenous MalformationChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownCombined Spinal-epidural AnesthesiaChina